Over the past few decades, several blood‐borne viruses have targeted haemophilia patients requiring treatment with clotting factors derived from human plasma.1 Even today, many haemophilia patients and their families still retain painful and indelible memories of HIV and hepatitis C infections or are confronted with the progressive health consequences of these infections. [...]
Hermans, C., Weill, A., & Pierce, G. F. (2020). The COVID-19 pandemic: New global challenges for the haemophilia community. Haemophilia (Print), 26(3), 371-372. https://doi.org/10.1111/hae.14001 (Original work published 2020)